首页> 美国卫生研究院文献>ACS AuthorChoice >Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels–Alder Click Chemistry
【2h】

Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels–Alder Click Chemistry

机译:基于反电子需量Diels–Alder Click化学的正电子发射断层扫描放射金属抗体构建的模块化策略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A modular system for the construction of radiometalated antibodies was developed based on the bioorthogonal cycloaddition reaction between 3-(4-benzylamino)-1,2,4,5-tetrazine and the strained dienophile norbornene. The well-characterized, HER2-specific antibody trastuzumab and the positron emitting radioisotopes 64Cu and 89Zr were employed as a model system. The antibody was first covalently coupled to norbornene, and this stock of norbornene-modified antibody was then reacted with tetrazines bearing the chelators 1,4,7,10-tetraazacyclo-dodecane-1,4,7,10-tetraacetic acid (DOTA) or desferrioxamine (DFO) and subsequently radiometalated with 64Cu and 89Zr, respectively. The modification strategy is simple and robust, and the resultant radiometalated constructs were obtained in high specific activity (2.7–5.3 mCi/mg). For a given initial stoichiometric ratio of norbornene to antibody, the 64Cu-DOTA- and 89Zr-DFO-based probes were shown to be nearly identical in terms of stability, the number of chelates per antibody, and immunoreactivity (>93% in all cases). In vivo PET imaging and acute biodistribution experiments revealed significant, specific uptake of the 64Cu- and 89Zr-trastuzumab bioconjugates in HER2-positive BT-474 xenografts, with little background uptake in HER2-negative MDA-MB-468 xenografts or other tissues. This modular system—one in which the divergent point is a single covalently modified antibody stock that can be reacted selectively with various chelators—will allow for both greater versatility and more facile cross-comparisons in the development of antibody-based radiopharmaceuticals.
机译:基于3-(4-苄基氨基)-1,2,4,5-四嗪与应变的亲二烯基降冰片烯之间的生物正交环加成反应,开发了用于构建放射性金属化抗体的模块系统。使用特征明确的,HER2特异性抗体曲妥珠单抗和发射正电子的放射性同位素 64 Cu和 89 Zr作为模型系统。首先将抗体与降冰片烯共价偶联,然后使该降冰片烯修饰的抗体与带有螯合剂1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)的四嗪反应或去铁胺(DFO),然后分别用 64 Cu和 89 Zr辐射金属化。修饰策略简单而稳健,并以高比活度(2.7–5.3 mCi / mg)获得了放射性金属化的构建体。对于给定的降冰片烯与抗体的化学计量比,基于稳定性的 64 Cu-DOTA-和 89 Zr-DFO探针显示几乎相同,每个抗体的螯合物数量和免疫反应性(在所有情况下均> 93%)。体内PET成像和急性生物分布实验表明,HER2阳性BT-474异种移植物中显着,特异性地摄取了 64 Cu-和 89 Zr-曲妥珠单抗生物共轭物,几乎没有背景HER2阴性MDA-MB-468异种移植物或其他组织的摄取。这种模块化系统(发散点是可以与各种螯合剂选择性反应的单一共价修饰的抗体原液)将在开发基于抗体的放射性药物时既具有更大的通用性,又可以进行更轻松的交叉比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号